Medicare Part D Comes Of Age: Most Beneficiaries Now In Fully Integrated Plans
Executive Summary
Part D has reached a significant milestone: for the first time, a majority of beneficiaries in the outpatient drug program are also enrolled in fully integrated Medicare Advantage plans. That opens up opportunities to learn more about value-based designs and longer-term outcomes.
You may also be interested in...
Medicare Value-Based Model May Provide Test For Biosimilars – At Some Point
Rheumatoid arthritis will be included in broaden clinical categories for year two of the value-based insurance design pilot; it may be an interesting test case for biosimilars.
Playing Offense in Part D: Three Aggressive Medicare Strategies Demand Pharma Attention
Humana thrilled CMS-and shocked its competitors-by offering stand-alone drug insurance plans under Medicare for less than $10 per month. Pharmaceutical manufacturers should applaud. Not all Part D strategies are equal for pharma companies. Manufacturers should compare Humana's approach to other aggressive bids by UnitedHealth and WellCare.
NASH Accelerated Approval: US FDA Remains Confident In Pathway For Liver Disease
A two-day workshop on potential biomarkers in NASH provided a forum for US FDA officials to offer implicit reassurance to drug developers: the agency stands behind its guidance on Accelerated Approval for the liver disease, despite the rejection of the first application seeking to use that approach.